fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 21 Sep 2026

POLICYBZR, full dossier

Overall Waiver of Premium adoption rose from 27% in FY24-25 to 29% in FY25-26 and 46% in FY26-27 year-to-date through August.

2 publishers have reported this development. Each act of reporting is below, cited.

The record

Overall Waiver of Premium adoption rose from 27% in FY24-25 to 29% in FY25-26 and 46% in FY26-27 year-to-date through August.

fortuneindia.com21 Sep 2026

Policybazaar data shows adoption of Waiver of Premium rose from 27% in FY2024-25 to 29% in FY2025-26 and 46% in FY2026-27 so far.

cnbctv18.com21 Sep 2026

PB Fintech

₹980.00

▼ -7.89%

Close (EOD), as of 1 Oct 2026 · source

PB Fintech: results, dividends, orders, the full cited record →

More on PB Fintech

PB Fintech shares have plunged 50% from their all-time high, falling below their 2021 IPO price of Rs 980 per share.

1 Oct 2026 · 1 publisher

PB Fintech expects a severe impact on its general insurance segment, with the segment’s revenue net present value potentially falling to around one-third to 40% of current levels.

30 Sep 2026 · 1 publisher

BSE and NSE have placed PB Fintech under the short-term Additional Surveillance Measure framework.

30 Sep 2026 · 1 publisher

PB Fintech's core online insurance revenue could face a 30% reduction in FY28 if IRDAI's proposed commission rules are implemented as drafted.

30 Sep 2026 · 2 publishers

PB Fintech slumped 6.11% to Rs 1,081 on Tuesday, extending its decline to 42.69% in four trading sessions.

30 Sep 2026 · 9 publishers

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.